STING: An Attractive Target for Autoimmune and Inflammatory Diseases.

Zhenjiao Yang, Xinqiao Liu, Jinhong Zhan, Mingliang Ma, Yuanxiang Wang

Abstract readReview

In one paragraph

Review in Medicinal research reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhenjiao YangBalance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.

Xinqiao LiuBalance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.

Jinhong ZhanBalance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.

Mingliang MaShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.

Yuanxiang WangBalance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.

Funding

Guangdong Basic and Applied Basic Research Foundation 2025A1515010632Guangdong Basic and Applied Basic Research Foundation 2026A1515010776NHC Key Laboratory of Nuclear Technology Medical Transformation 2025HYX012

6 · The paper itself

Abstract

Stimulator of Interferon Genes (STING) is a transmembrane homodimer protein located in the endoplasmic reticulum membrane and plays an essential role in human innate immunity. Hyperactivation of STING has been found in many autoimmune and inflammatory diseases. Therefore, STING has been recognized as a promising target for the treatment of these diseases. Many efforts have been devoted to identifying STING inhibitors and degraders. However, development of STING drug candidates is still challenging and in its infancy, and no candidates have been advanced into clinical trials. In this perspective, we comprehensively summarize recent advances in the development of STING inhibitors and degraders and highlight their design strategies. We also discuss the challenges and opportunities of STING inhibition and expect to shed light on future STING drug discovery.

Indexed as

Autoimmune DiseasesInflammationMembrane ProteinsAnimalsHumansSTING ProteinMembrane ProteinsSTING1 protein, humanSTING Proteinautoimmuneinflammatory diseasesPROTACsmall‐molecule inhibitorsSTING

Identifiers

PMID42131945

DOI10.1002/med.70058

PMCPMC13441384

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.